We and others found that EPO and the HIF‐PHDi FG‐4592 raised FGF23 production in vitro and in vivo when given acutely (Clinkenbeard et al., 2017; David et al., 2016; Hanudel, Eisenga, et al., 2018); however, the effects of these therapeutic agents on circulating FGF23 concentrations during anemia, and its downstream effects on mineral metabolism, are unknown. Here, EPO is linked to anemia (phenotype).